AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / GOLD AND SILVER ORES
XORTX Therapeutics Inc. Common Stock
XNAS · usd
SIC 1081 · GOLD AND SILVER ORES
FIGI BBG009J96Z06
0.92▼ 0.05 (-5.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.97
Day's Range
0.92 – 0.95
52-Week Range
0.34 – 3.60
Volume
17.5K
Avg Volume
1.0M
Share Statistics
Shares Outstanding
Employees
3
Exchange
XNAS
Listed
2018-05-04
Share count as of December 31, 2025

XORTX Therapeutics Inc. Common Stock (XRTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about XORTX Therapeutics Inc. Common Stock (XRTX)
What is XORTX Therapeutics Inc. Common Stock's Market Cap?
XORTX Therapeutics Inc. Common Stock's Market Cap is $6.4M, based on as-reported figures from SEC (XBRL) filings.
What is XORTX Therapeutics Inc. Common Stock's Enterprise Value?
XORTX Therapeutics Inc. Common Stock's Enterprise Value is $5.5M, based on as-reported figures from SEC (XBRL) filings.
What is XORTX Therapeutics Inc. Common Stock's Net Income (TTM)?
XORTX Therapeutics Inc. Common Stock's Net Income (TTM) is -$2.7M, based on as-reported figures from SEC (XBRL) filings.
What is XORTX Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
XORTX Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -0.38, based on as-reported figures from SEC (XBRL) filings.
What is XORTX Therapeutics Inc. Common Stock's Net Debt?
XORTX Therapeutics Inc. Common Stock's Net Debt is -$864.5K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XRTXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Expenses
Research and development
Consulting, wages and benefits
Directors' fees
Investor relations
Professional fees
General and administrative
Public company costs
Travel
Amortization of property and equipment
Amortization of intangible assets
Impairment of intangible assets
Share-based payments
Loss before other items
Fair value adjustment on derivative warrant liability
Foreign exchange loss
Interest income
Transaction costs on derivative warrant liability—
Items that may be subsequently reclassified to profit or loss:
Total loss and comprehensive loss for the year
Basic and diluted loss per common share
Basic loss per common share
Diluted loss per common share